ProtAffin AG signs manufacturing contract for PA401 with CMC Biologics A/S

29-Jul-2010 - Denmark

ProtAffin AG announced it has signed a manufacturing contract with CMC Biologics’ Danish operations, located in Copenhagen, Denmark for manufacture of its lead product PA401 for the treatment of chronic obstructive pulmonary disease (COPD). The contract will cover manufacture and supply of PA401 for preclinical development and early clinical development in COPD and related respiratory indications. PA401 is a glycan-binding decoy protein based on human chemokine IL-8 (CXCL8), which has shown potent anti-inflammatory activity in both chronic and acute preclinical models of lung inflammation. A composition of matter patent covering PA401 has been granted in the USA and the EU.

ProtAffin’s novel class of biopharmaceutical products are first-in-class engineered versions of human proteins which bind to cell surface glycans (sugars) to affect their biological activity. Specific cell surface glycans underlie inflammatory processes in several diseases including COPD, and represent a rich and relatively under-investigated class of potential drug targets for pharmaceutical and biotechnology companies. ProtAffin’s approach is entirely innovative and opens up glycans as druggable targets through the use of its CellJammer® discovery technology.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

Ocean Optics Names Winner of 2012 Young Investigator Award - Cash prize and grant awarded during SPIE BiOS/Photonics West 2012 conference

Ocean Optics Names Winner of 2012 Young Investigator Award - Cash prize and grant awarded during SPIE BiOS/Photonics West 2012 conference

Real-Time Monitoring of Bioprocesses - IRUBIS closes EUR 2.8m seed round led by HTGF, Verve Ventures and Ventura BioMed Investors

Real-Time Monitoring of Bioprocesses - IRUBIS closes EUR 2.8m seed round led by HTGF, Verve Ventures and Ventura BioMed Investors

Acambis extends Sanofi Pasteur licensing agreement on single-dose JE vaccine to India and Indian subcontinent

Exiqon A/S wins prestigious Ernst & Young Entrepreneur of the Year Award

Bio-Rad Announces Receipt of New Ruling in Applied Biosystems Patent Infringement Dispute

Sandoz completes acquisition of EBEWE Pharma, improving global patient access to affordable injectable cancer medicines - Sandoz to focus on quick and seamless integration for customers and employees

Eckert & Ziegler acquires Vitalea Science Inc. as Part of Strategic Move into Innovative Pharmaceutical Services

Albumin preserves kidney function and improves survival in abdominal infection of liver disease

Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations

UCB to sell its U.S. specialty generics business Kremers Urban for US$ 1,525 million

Evotec and Novo Nordisk form research alliance in diabetes and obesity

CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema - Phase I/II study to establish safety and clinical pharmacology with various doses of subcutaneous formulation of human C1-esterase inhibitor